MHC-class II restricted melanoma antigens and their use in...

Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S324000, C530S325000, C530S326000, C530S327000, C530S350000, C530S402000, C530S403000, C424S185100, C424S192100, C424S193100, C424S277100, C424S093710

Reexamination Certificate

active

06951917

ABSTRACT:
The present invention provides MHC Class II restricted melanoma antigens recognized by CD4+T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.

REFERENCES:
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5679511 (1997-10-01), Kwon
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 3341367 (1984-05-01), None
patent: 0668350 (1995-08-01), None
patent: 0 679 660 (1995-11-01), None
patent: 2133543 (1984-08-01), None
patent: WO 88/02372 (1988-04-01), None
patent: 9314189 (1993-07-01), None
patent: 9405304 (1994-03-01), None
patent: 9414459 (1994-07-01), None
patent: 9423067 (1994-10-01), None
patent: WO 95 00849 (1995-01-01), None
patent: 9522561 (1995-08-01), None
patent: WO 95 23234 (1995-08-01), None
Rammensee et al (Immunogenetics (1995) 41:175-177).
Razzaque et al. Vaccine 19:644-647 (2001).
Rosenberg, Immunology Today 18(4):175-182.
Janeway et al. Immunbiology (1999) Garland Press NY p. 122.
Bohinski, Modern Concepts in Biochem., 5th ed., p. 66-68, 1987.
Salgaller et al. Cancer Immunol. Immunother. 39:105-116, 1994.
Parker et al. J. Immunol. 149:3580-87, Dec. 1992.
Englehard, V.H. Current Opinion in Immunology 6:13-23, 1994.
Burgess et al. J. Cell Biol. 111:2129-38, Nov. 1990.
Lazar et al. Mol. Cell Biol. 8(3):1247-52, Mar. 1988.
Chicz, R.M., et al., “Specificity And Promiscuity Among Naturally Processed Peptides Bound To HLA-Dr Alleles”J. Exp. Med., 178, 27-47; (1993).
Sette, A. et al., “Capacity Of Intact Proteins To Bind To MHC Class II Molecules”J. Immunol., 143, 1265-1267; (1989).
Brown, J.H., et al. “Three-Dimensional Structure Of The Human Class II Histocompatability Antigen HLA-DRI”Nature, 364, 33-39 (1993).
Kwon, et al., “Isolation And Sequence Of A cDNA Clone For Human Tyrosinanse That Maps At The Mouse c-Albino Locus”PNAS, 84:7473-7477, (1987).
Shibihara, S. et al., “Molecular Basis For The Heterogeneity Of Human Tyrosinase”J. Exp. Med, 156:403-414, (1988).
Sette, A. et al., “HLA-DR4w4-Binding Motifs Illustrate The Bio chemical Basis Of Degeneracy And Specificity In Peptide-Dr Interactions”J. Immunol., 151:3163-3170, (1993).
Rammensee, H.G. et al., “MHC Ligands And Peptide Motifs: First Listing”Immunogenetics, 41:178-228 (1995).
Kozono, H. et al., “Production Of Soluble MHC II Class II Proteins With Covalently Bound Single Peptides”Nature, 369:151-154 (1994).
Sinigaglia, F. et al., “Motifs And Super motifs for MHC Class II Binding Peptides”J. Exp. Med., 181:449-451 (1995).
Kawakami, et al., “Cloning Of The Gene Coding For A Shared Human Melanoma Antigen Recognized By Autologous T-Cells Infiltrating Into Tumor”Proc. Natl. Acad. Sci., 91:3575-3579 (1994).
Wang, R-F et al., “Identification Of A Gene Encoding A Melanoma Tumor Antigen Recognized By HLA-A31-Resricted Tumor Infiltrating Lumpitocytes”J. Exp. Med., 181:799-804, (1995).
Sidney, J. et al., “DR B1* 0301 Molecules Recognize A Structural Motif Distinct From The One Recognized By Most DR B, Alleles”J. Immunol., 149, 2634-2640, (1992).
Malcherek, G. et al., “Super Motifs Enable Natural Invariant Chain-derived Peptides To Interact With Many Major Histocompatability Complex-class II Molecules”J. Exp. Med., 181, 527-536 (1995).
Topalian, S., “MHC Class II Restricted Tumor Antigens And The Role Of CD4+ T Cells In Cancer Antigens”Current Opinion in Immunology, 6:741-745, (1994).
Topalian, S., et al. (1994) “Melanoma Specific CD4+ T-Lymphocytes Recognize Human Melanoma Antigens Processed And Presented By Epstein Barr Virus Transformed Cells”Int. J. Cancer58:69-79.
Nanda, et al., “Induction of Anti Self-Immunity to Bone Cancer”Cell, 82:13-17, (1995).
Markus, N. et al., “Analysis of Cytokine Secretion by Melanoma-Specific CDY&Lymphocytes” Journal of Interferon and Cytokine Research, 15:739-746, (1995).
GenBank, Acession No. J03581—Jan. 14, 1995.
GenBank, Acession No. U01873—Sep. 27, 1993.
GenBank, Acession No. Y00819—Jul. 28, 1995.
GenBank, Acession No. M27160—Jul. 28, 1995.
Coulie, P.G. et al. (1993) “Genes coding for tumor antigens recognized by cytolytic T-lymphocytes.”J. Immunotherap.; 14:104-109.
Coulie P.G. et al. “A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.”J. Exp. Med.1994; 180:35-42.
Maresh, C.A. et al.: “Cloning and expression of the gene for the melanoma associated ME20 antigen.”DNA and Cell Biology1994; 13:87-95.
Cox, A.L., et al. “Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.”Science1994; 264:716-719.
Brichard, V., et al.: “The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas”.J. Exp. Med.1993; 178:489-495.
Gaugler, B., et al. “Human gene MAGE-3 codes for an antigen recognized on a mnelanoma by autologous cytolytic T lymphocytes”.J. Exp. Med.1994; 179:921-930.
Traversari, C., et al.: “A nonpeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E”.J. Exp. Med.1992; 176:1453-1457.
Cellis, E., et al.: “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptides epitopes”.Proc. Natl. Acad. Sci. USA1994; 91:2105-2109.
Boon, T.: “Toward a genetic analysis of tumor rejection antigens”.Adv. Cancer Res.1992; 58:177-210.
Kawakami, Y., et al.: “T-cell recognition of human melanoma antigens.”J. Immunother.1993; 14:88-93.
Bakker, A.B.H., et al.: “Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor infiltrating lymphocytes.”J. Exp. Med.1994; 179:1005-1009.
Wölfel, T., et al.: “Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T. lymphocytes.”Eur. J. Immunol.1994; 24:759-764.
Rosenberg, S.A., et al.: “Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report.”N. Engl. J. Med.1988; 319:1676-1680.
Kawakami, Y., et al.,: “Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1 transfected melanomas.”J. Immunol1992; 148:638-643.
Van der Bruggen, et al.: “A gene encoding an antigen recognized by cytolytic T. lymphocytes on a human melanoma.”Science1991; 254:1643-1647.
Falk, K., et al.: “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.”Nature1991; 351:290-296.
Kubo, R., et al.: “Definition of specific peptide motifs for four major HLA-A Alleles.”Journal of Immunology1994, 152:3913-3924.
Parker, K., et al.: “Sequence motifs important for peptide binding to the human MHC class 1 molecule. HLA-A2.”J. Immunol.1992; 3580-3587.
Ruppert, J., et al.: “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules.”Cell1993; 74:929-937.
Storkus, W., et al.: “Identification of human melanoma peptides recognized by class 1 restricted tumor infiltrating T lymphocytes.”Journal of Immunology1993; 151:3719-3727.
Kawakami, Y., et al.: “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T c

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

MHC-class II restricted melanoma antigens and their use in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MHC-class II restricted melanoma antigens and their use in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MHC-class II restricted melanoma antigens and their use in... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3444240

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.